RxDoctor Payments Data

Rafael Medina-Prieto

Gastroenterology · Cayey, PRNPI 1235660762

Payments from drug & device makers

$2,916in general payments, 2019–2025

Across 54 payments — averaging $54.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • E.r. Squibb & Sons, L.L.C.$529
  • Ferring Pharmaceuticals Inc.$177
  • Olympus Latin America, Inc.$147
  • Sanofi$140
  • Takeda Pharmaceuticals U.S.A., Inc.$139
  • plus $275 from 6 others

What the payments were for

  • Food & beverage$2,916100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie29$1,508
E.r. Squibb & Sons, L.L.C.11$529
Ferring Pharmaceuticals Inc.1$177
Olympus Latin America, Inc.1$147
Sanofi1$140
Takeda Pharmaceuticals U.S.A., Inc.2$139
Boston Scientific1$103
Johnson & Johnson3$68
Amgen2$40
Gilead1$25
PBG Puerto Rico LLC1$21
Organon1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,916 in reported general payments places this provider in the 60th percentile of 198 gastroenterology providers in Puerto Rico.

See all gastroenterology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$4,392
Medicare patients
15
Services billed
28

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SuprepSodium, Potassium,mag Sulfates107$12,678
LinzessLinaclotide11$5,973
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates62$5,298
Omeprazole110$511
Midazolam HclMidazolam Hcl/Pf138$391
Metronidazole25$376
Sodium Chloride0.9 % Sodium Chloride58$348
Fentanyl CitrateFentanyl Citrate/Pf89$291
Doxycycline Hyclate16$256
Naloxone Hcl12$174
Famotidine23$167
Pantoprazole Sodium21$159
Midazolam Hcl23$62

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,508$5,97311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 198 gastroenterology providers in Puerto Rico.

Other gastroenterology in Cayey

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →